384 related articles for article (PubMed ID: 23475125)
1. Disruption of lamin B1 and lamin B2 processing and localization by farnesyltransferase inhibitors.
Adam SA; Butin-Israeli V; Cleland MM; Shimi T; Goldman RD
Nucleus; 2013; 4(2):142-50. PubMed ID: 23475125
[TBL] [Abstract][Full Text] [Related]
2. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.
Wang Y; Ostlund C; Choi JC; Swayne TC; Gundersen GG; Worman HJ
Nucleus; 2012; 3(5):452-62. PubMed ID: 22895092
[TBL] [Abstract][Full Text] [Related]
3. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
5. Farnesylation of lamin B1 is important for retention of nuclear chromatin during neuronal migration.
Jung HJ; Nobumori C; Goulbourne CN; Tu Y; Lee JM; Tatar A; Wu D; Yoshinaga Y; de Jong PJ; Coffinier C; Fong LG; Young SG
Proc Natl Acad Sci U S A; 2013 May; 110(21):E1923-32. PubMed ID: 23650370
[TBL] [Abstract][Full Text] [Related]
6. Lamin A-linked progerias: is farnesylation the be all and end all?
Smallwood DT; Shackleton S
Biochem Soc Trans; 2010 Feb; 38(Pt 1):281-6. PubMed ID: 20074075
[TBL] [Abstract][Full Text] [Related]
7. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
Wang Y; Ostlund C; Worman HJ
Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
[TBL] [Abstract][Full Text] [Related]
8. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
Toth JI; Yang SH; Qiao X; Beigneux AP; Gelb MH; Moulson CL; Miner JH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12873-8. PubMed ID: 16129834
[TBL] [Abstract][Full Text] [Related]
9. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.
Yang SH; Bergo MO; Toth JI; Qiao X; Hu Y; Sandoval S; Meta M; Bendale P; Gelb MH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10291-6. PubMed ID: 16014412
[TBL] [Abstract][Full Text] [Related]
10. The truncated prelamin A in Hutchinson-Gilford progeria syndrome alters segregation of A-type and B-type lamin homopolymers.
Delbarre E; Tramier M; Coppey-Moisan M; Gaillard C; Courvalin JC; Buendia B
Hum Mol Genet; 2006 Apr; 15(7):1113-22. PubMed ID: 16481358
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells.
Mehta IS; Eskiw CH; Arican HD; Kill IR; Bridger JM
Genome Biol; 2011 Aug; 12(8):R74. PubMed ID: 21838864
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
Mallampalli MP; Huyer G; Bendale P; Gelb MH; Michaelis S
Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14416-21. PubMed ID: 16186497
[TBL] [Abstract][Full Text] [Related]
13. Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors.
Rusiñol AE; Sinensky MS
J Cell Sci; 2006 Aug; 119(Pt 16):3265-72. PubMed ID: 16899817
[TBL] [Abstract][Full Text] [Related]
14. Nuclear localization signal deletion mutants of lamin A and progerin reveal insights into lamin A processing and emerin targeting.
Wu D; Flannery AR; Cai H; Ko E; Cao K
Nucleus; 2014; 5(1):66-74. PubMed ID: 24637396
[TBL] [Abstract][Full Text] [Related]
15. Hutchinson-Gilford progeria syndrome through the lens of transcription.
Prokocimer M; Barkan R; Gruenbaum Y
Aging Cell; 2013 Aug; 12(4):533-43. PubMed ID: 23496208
[TBL] [Abstract][Full Text] [Related]
16. Genetic and pharmacological modulation of lamin A farnesylation determines its function and turnover.
Foo MXR; Ong PF; Yap ZX; Maric M; Bong CJS; Dröge P; Burke B; Dreesen O
Aging Cell; 2024 May; 23(5):e14105. PubMed ID: 38504487
[TBL] [Abstract][Full Text] [Related]
17. Prelamin A farnesylation and progeroid syndromes.
Young SG; Meta M; Yang SH; Fong LG
J Biol Chem; 2006 Dec; 281(52):39741-5. PubMed ID: 17090536
[TBL] [Abstract][Full Text] [Related]
18. CTP:phosphocholine cytidylyltransferase α (CCTα) and lamins alter nuclear membrane structure without affecting phosphatidylcholine synthesis.
Gehrig K; Ridgway ND
Biochim Biophys Acta; 2011 Jun; 1811(6):377-85. PubMed ID: 21504799
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
20. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
